Valneva SE reported first half 2026 financial results with total product sales of €64.0 million and reaffirmed its full-year guidance of €135 to €150 million in product sales. The company posted a net loss of €63.3 million for the six months ended June 30, 2026, compared with a net loss of €20.8 million in the same period of 2025, reflecting lower gross margin due to lower sales and manufacturing volumes as well as one-off impacts on cost of goods sold, including IXCHIQ-related contract termination costs and inventory write-offs. Valneva's cash position stood at €121.5 million as of end June 2026, up from €109.7 million at December 31, 2025, supported by disciplined cash management and €37 million in gross proceeds from a reserved offering completed in the second quarter. The company also implemented a global restructuring program expected to have positive profit and loss and cash flow impacts in the second half of the year and beyond, including a workforce reduction and the agreed sale of its Nantes site in France for €6.2 million. Regulatory decisions for the Lyme disease vaccine candidate LB6V, partnered with Pfizer, are expected in the next twelve months, with Pfizer expressing optimism about obtaining registration.
Valneva SENet loss widened due to lower sales, manufacturing volumes, and one-off costs.
Pfizer IncPfizer's optimism about LB6V registration is positive for its vaccine pipeline.
